Advertisement

Relation of Stroke and Major Bleeding to Creatinine Clearance in Patients With Atrial Fibrillation (from the Fushimi AF Registry)

Published:January 25, 2017DOI:https://doi.org/10.1016/j.amjcard.2017.01.005
      Creatinine clearance (CrCl) has been widely used to adjust the dosage of non–vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (AF) and exclude contraindicated patients. However, there are few available real-world data on the relation between CrCl and adverse clinical outcomes in patients with AF. Therefore, we evaluated the clinical characteristics and adverse events in Japanese patients with AF stratified by CrCl. We categorized patients in the Fushimi AF Registry, a large prospective community-based Japanese cohort of patients with AF, into 3 groups as follows: (1) CrCl <30 ml/min, (2) CrCl 30 to 49 ml/min, and (3) CrCl ≥50 ml/min. We evaluated 3,080 patients after a median follow-up of 1,076 days. Comparing with patients with CrCl ≥50 ml/min, patients with AF with CrCl <30 ml/min showed increased risks of stroke/systemic embolism (SE) (hazard ratio [HR] 1.68; 95% confidence interval [CI] 1.04 to 2.65; p = 0.04) and major bleeding (HR, 2.08; 95% CI 1.23 to 3.39; p = 0.008) after adjustment for prespecified factors. Patients with AF with CrCl <30 ml/min were also associated with higher risks of all-cause death, hospitalization for heart failure, myocardial infarction, or the composite of all-cause death and stroke/SE. However, no excess risk of stroke/SE (HR 1.10; 95% CI 0.76 to 1.58; p = 0.6) or major bleeding (HR 0.98; 95% CI 0.63 to 1.48; p = 0.9) was noted for patients with CrCl 30 to 49 ml/min. In conclusion, Japanese patients with AF with CrCl <30 ml/min were closely associated with adverse clinical events including stroke/SE and major bleeding.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Olesen J.B.
        • Lip G.Y.
        • Kamper A.L.
        • Hommel K.
        • Kober L.
        • Lane D.A.
        • Lindhardsen J.
        • Gislason G.H.
        • Torp-Pedersen C.
        Stroke and bleeding in atrial fibrillation with chronic kidney disease.
        N Engl J Med. 2012; 367: 625-635
        • Marinigh R.
        • Lane D.A.
        • Lip G.Y.
        Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk.
        J Am Coll Cardiol. 2011; 57: 1339-1348
        • Hohnloser S.H.
        • Hijazi Z.
        • Thomas L.
        • Alexander J.H.
        • Amerena J.
        • Hanna M.
        • Keltai M.
        • Lanas F.
        • Lopes R.D.
        • Lopez-Sendon J.
        • Granger C.B.
        • Wallentin L.
        Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.
        Eur Heart J. 2012; 33: 2821-2830
        • Apostolakis S.
        • Guo Y.
        • Lane D.A.
        • Buller H.
        • Lip G.Y.
        Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial.
        Eur Heart J. 2013; 34: 3572-3579
        • Masson P.
        • Webster A.C.
        • Hong M.
        • Turner R.
        • Lindley R.I.
        • Craig J.C.
        Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis.
        Nephrol Dial Transplant. 2015; 30: 1162-1169
        • Jun M.
        • James M.T.
        • Manns B.J.
        • Quinn R.R.
        • Ravani P.
        • Tonelli M.
        • Perkovic V.
        • Winkelmayer W.C.
        • Ma Z.
        • Hemmelgarn B.R.
        The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study.
        BMJ. 2015; 350: h246
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • Eikelboom J.
        • Oldgren J.
        • Parekh A.
        • Pogue J.
        • Reilly P.A.
        • Themeles E.
        • Varrone J.
        • Wang S.
        • Alings M.
        • Xavier D.
        • Zhu J.
        • Diaz R.
        • Lewis B.S.
        • Darius H.
        • Diener H.C.
        • Joyner C.D.
        • Wallentin L.
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Patel M.R.
        • Mahaffey K.W.
        • Garg J.
        • Pan G.
        • Singer D.E.
        • Hacke W.
        • Breithardt G.
        • Halperin J.L.
        • Hankey G.J.
        • Piccini J.P.
        • Becker R.C.
        • Nessel C.C.
        • Paolini J.F.
        • Berkowitz S.D.
        • Fox K.A.
        • Califf R.M.
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Granger C.B.
        • Alexander J.H.
        • McMurray J.J.
        • Lopes R.D.
        • Hylek E.M.
        • Hanna M.
        • Al-Khalidi H.R.
        • Ansell J.
        • Atar D.
        • Avezum A.
        • Bahit M.C.
        • Diaz R.
        • Easton J.D.
        • Ezekowitz J.A.
        • Flaker G.
        • Garcia D.
        • Geraldes M.
        • Gersh B.J.
        • Golitsyn S.
        • Goto S.
        • Hermosillo A.G.
        • Hohnloser S.H.
        • Horowitz J.
        • Mohan P.
        • Jansky P.
        • Lewis B.S.
        • Lopez-Sendon J.L.
        • Pais P.
        • Parkhomenko A.
        • Verheugt F.W.
        • Zhu J.
        • Wallentin L.
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Giugliano R.P.
        • Ruff C.T.
        • Braunwald E.
        • Murphy S.A.
        • Wiviott S.D.
        • Halperin J.L.
        • Waldo A.L.
        • Ezekowitz M.D.
        • Weitz J.I.
        • Spinar J.
        • Ruzyllo W.
        • Ruda M.
        • Koretsune Y.
        • Betcher J.
        • Shi M.
        • Grip L.T.
        • Patel S.P.
        • Patel I.
        • Hanyok J.J.
        • Mercuri M.
        • Antman E.M.
        Edoxaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2013; 369: 2093-2104
        • Heidbuchel H.
        • Verhamme P.
        • Alings M.
        • Antz M.
        • Diener H.C.
        • Hacke W.
        • Oldgren J.
        • Sinnaeve P.
        • Camm A.J.
        • Kirchhof P.
        Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
        Europace. 2015; 17: 1467-1507
        • Piccini J.P.
        • Stevens S.R.
        • Chang Y.
        • Singer D.E.
        • Lokhnygina Y.
        • Go A.S.
        • Patel M.R.
        • Mahaffey K.W.
        • Halperin J.L.
        • Breithardt G.
        • Hankey G.J.
        • Hacke W.
        • Becker R.C.
        • Nessel C.C.
        • Fox K.A.
        • Califf R.M.
        Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors in Atrial fibrillation) study cohorts.
        Circulation. 2013; 127: 224-232
        • Healey J.S.
        • Oldgren J.
        • Ezekowitz M.
        • Zhu J.
        • Pais P.
        • Wang J.
        • Commerford P.
        • Jansky P.
        • Avezum A.
        • Sigamani A.
        • Demasceno A.
        • Reilly P.
        • Grinvalds A.
        • Nakamya J.
        • Aje A.
        • Almahmeed W.
        • Moriarty A.
        • Wallentin L.
        • Yusuf S.
        • Connolly S.J.
        Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study.
        Lancet. 2016; 388: 1161-1169
        • Odutayo A.
        • Wong C.X.
        • Hsiao A.J.
        • Hopewell S.
        • Altman D.G.
        • Emdin C.A.
        Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis.
        BMJ. 2016; 354: i4482
        • Akao M.
        • Chun Y.H.
        • Wada H.
        • Esato M.
        • Hashimoto T.
        • Abe M.
        • Hasegawa K.
        • Tsuji H.
        • Furuke K.
        Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry.
        J Cardiol. 2013; 61: 260-266
        • Akao M.
        • Chun Y.H.
        • Esato M.
        • Abe M.
        • Tsuji H.
        • Wada H.
        • Hasegawa K.
        Inappropriate use of oral anticoagulants for patients with atrial fibrillation.
        Circ J. 2014; 78: 2166-2172
        • Hamatani Y.
        • Ogawa H.
        • Uozumi R.
        • Iguchi M.
        • Yamashita Y.
        • Esato M.
        • Chun Y.H.
        • Tsuji H.
        • Wada H.
        • Hasegawa K.
        • Abe M.
        • Morita S.
        • Akao M.
        Low body weight is associated with the incidence of stroke in atrial fibrillation patients—insight from the Fushimi AF Registry.
        Circ J. 2015; 79: 1009-1017
        • Yamashita Y.
        • Hamatani Y.
        • Esato M.
        • Chun Y.H.
        • Tsuji H.
        • Wada H.
        • Hasegawa K.
        • Abe M.
        • Lip G.Y.
        • Akao M.
        Clinical characteristics and outcomes in extreme elderly (age ≥85) Japanese patients with atrial fibrillation: the Fushimi AF Registry.
        Chest. 2016; 149: 401-412
        • Takabayashi K.
        • Hamatani Y.
        • Yamashita Y.
        • Takagi D.
        • Unoki T.
        • Ishii M.
        • Iguchi M.
        • Masunaga N.
        • Ogawa H.
        • Esato M.
        • Chun Y.H.
        • Tsuji H.
        • Wada H.
        • Hasegawa K.
        • Abe M.
        • Lip G.Y.
        • Akao M.
        Incidence of stroke or systemic embolism in paroxysmal versus sustained atrial fibrillation: the Fushimi atrial fibrillation registry.
        Stroke. 2015; 46: 3354-3361
        • Cockcroft D.W.
        • Gault M.H.
        Prediction of creatinine clearance from serum creatinine.
        Nephron. 1976; 16: 31-41
        • Schulman S.
        • Kearon C.
        Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.
        J Thromb Haemost. 2005; 3: 692-694
        • Thygesen K.
        • Alpert J.S.
        • Jaffe A.S.
        • Simoons M.L.
        • Chaitman B.R.
        • White H.D.
        • Katus H.A.
        • Apple F.S.
        • Lindahl B.
        • Morrow D.A.
        • Clemmensen P.M.
        • Johanson P.
        • Hod H.
        • Underwood R.
        • Bax J.J.
        • Bonow J.J.
        • Pinto F.
        • Gibbons R.J.
        • Fox K.A.
        • Atar D.
        • Newby L.K.
        • Galvani M.
        • Hamm C.W.
        • Uretsky B.F.
        • Steg P.G.
        • Wijns W.
        • Bassand J.P.
        • Menasche P.
        • Ravkilde J.
        • Ohman E.M.
        • Antman E.M.
        • Wallentin L.C.
        • Armstrong P.W.
        • Januzzi J.L.
        • Nieminen M.S.
        • Gheorghiade M.
        • Filippatos G.
        • Luepker R.V.
        • Fortmann S.P.
        • Rosamond W.D.
        • Levy D.
        • Wood D.
        • Smith S.C.
        • Hu D.
        • Lopez-Sendon J.L.
        • Robertson R.M.
        • Weaver D.
        • Tendera M.
        • Bove A.A.
        • Parkhomenko A.N.
        • Vasilieva E.J.
        • Mendis S.
        • Baumgartner H.
        • Ceconi C.
        • Dean V.
        • Deaton C.
        • Fagard R.
        • Funck-Brentano C.
        • Hasdai D.
        • Hoes A.
        • Kirchhof P.
        • Knuuti J.
        • Kolh P.
        • McDonagh T.
        • Moulin C.
        • Popescu B.A.
        • Reiner Z.
        • Sechtem U.
        • Sirnes P.A.
        • Torbicki A.
        • Vahanian A.
        • Windecker S.
        • Morais J.
        • Aguiar C.
        • Almahmeed W.
        • Arnar D.O.
        • Barili F.
        • Bloch K.D.
        • Bolger A.F.
        • Botker H.E.
        • Bozkurt B.
        • Bugiardini R.
        • Cannon C.
        • de Lemos J.
        • Eberli F.R.
        • Escobar E.
        • Hlatky M.
        • James S.
        • Kern K.B.
        • Moliterno D.J.
        • Mueller C.
        • Neskovic A.N.
        • Pieske B.M.
        • Schulman S.P.
        • Storey R.F.
        • Taubert K.A.
        • Vranckx P.
        • Wagner D.R.
        Third universal definition of myocardial infarction.
        J Am Coll Cardiol. 2012; 60: 1581-1598
        • Gage B.F.
        • Waterman A.D.
        • Shannon W.
        • Boechler M.
        • Rich M.W.
        • Radford M.J.
        Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.
        JAMA. 2001; 285: 2864-2870
        • Lip G.Y.
        • Nieuwlaat R.
        • Pisters R.
        • Lane D.A.
        • Crijns H.J.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation.
        Chest. 2010; 137: 263-272
        • Pisters R.
        • Lane D.A.
        • Nieuwlaat R.
        • de Vos C.B.
        • Crijns H.J.
        • Lip G.Y.
        A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
        Chest. 2010; 138: 1093-1100
        • Okumura K.
        • Inoue H.
        • Atarashi H.
        • Yamashita T.
        • Tomita H.
        • Origasa H.
        Validation of CHA(2)DS(2)-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry.
        Circ J. 2014; 78: 1593-1599
        • Goto K.
        • Nakai K.
        • Shizuta S.
        • Morimoto T.
        • Shiomi H.
        • Natsuaki M.
        • Yahata M.
        • Ota C.
        • Ono K.
        • Makiyama T.
        • Nakagawa Y.
        • Furukawa Y.
        • Kadota K.
        • Takatsu Y.
        • Tamura T.
        • Takizawa A.
        • Inada T.
        • Doi O.
        • Nohara R.
        • Matsuda M.
        • Takeda T.
        • Kato M.
        • Shirotani M.
        • Eizawa H.
        • Ishii K.
        • Lee J.D.
        • Takahashi M.
        • Horie M.
        • Miki S.
        • Aoyama T.
        • Suwa S.
        • Hamasaki S.
        • Ogawa H.
        • Mitsudo K.
        • Nobuyoshi M.
        • Kita T.
        • Kimura T.
        Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
        Am J Cardiol. 2014; 114: 70-78
        • Wan Y.
        • Heneghan C.
        • Perera R.
        • Roberts N.
        • Hollowell J.
        • Glasziou P.
        • Bankhead C.
        • Xu Y.
        Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review.
        Circ Cardiovasc Qual Outcomes. 2008; 1: 84-91